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Objectives This study sought to investigate the long-term effectiveness of drug-eluting stents (DES)
versus bare-metal stents (BMS).
Background Improved recanalization techniques have increased interest in percutaneous coronary interven-
tion (PCI) for chronic total coronary occlusion (CTO). The long-term effectiveness of DES and BMS is not
known.
Methods We used data from 10,261 stable patients age 65 years at 889 U.S. hospitals who under-
went CTO PCI from January 1, 2005, to December 31, 2008, in the NCDR (National Cardiovascular
Data Registry) CathPCI Registry with linked Medicare inpatient claims for follow-up. Patient and pro-
cedural characteristics, and 30-month death, myocardial infarction, revascularization, and hospitaliza-
tion for bleeding were evaluated by stent type. Outcomes following stenting were adjusted and
compared using propensity score matching.
Results DES were used for CTO PCI in 8,218 (80%) and BMS in 2,043 (20%). DES patients were
younger (74.0 vs. 75.5 years, p  0.001), had longer lesions (18.8 vs. 16.5 mm, p  0.001), received
more stents (2 stents in 45.7% vs. 37.9%, p  0.001), and underwent multivessel PCI (18.9% vs.
15.1%, p  0.001). DES implantation was associated with a lower hazard of mortality (hazard ratio
[HR]:  0.72, 95% conﬁdence interval [CI]: 0.60 to 0.86, p  0.001), a similar hazard for myocardial
infarction (HR: 0.85, 95% CI: 0.61 to 1.19, p  0.35), and subsequent revascularization (HR: 0.94, 95%
CI: 0.79 to 1.12, p  0.48), including PCI (HR: 0.98, 95% CI: 0.83 to 1.19, p  0.87) and coronary ar-
tery bypass grafting (HR: 0.71, 95% CI: 0.46 to 1.10, p  0.12). Hospitalization for bleeding was also
similar for DES versus BMS (HR: 0.92; 95% CI: 0.61 to 1.39, p  0.70).
Conclusions Compared with BMS, DES use in stable patients undergoing CTO PCI was associated with
lower mortality, as well as similar myocardial infarction and repeat revascularization rates without an in-
crease in subsequent bleeding requiring hospitalization. (J Am Coll Cardiol Intv 2012;5:1054–61)
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1055The benefit of percutaneous revascularization in patients
with chronic total coronary occlusions (CTO) depends on
both successful recanalization of the vessel and durable
long-term patency. These challenges are evident as the
presence of a total coronary occlusion increases the com-
plexity score for percutaneous revascularization (1), and
presence of a total coronary occlusion remains 1 of the
strongest predictors of a referral for coronary bypass surgery.
The complexity of this decision is further amplified in
elderly patients in whom the risks of revascularization (with
either percutaneous coronary intervention [PCI] or bypass
surgery) are increased.
Recent advances in percutaneous techniques for recanalization
(2) have increased focus on stent choice and the challenge of
maintaining patency. Although drug-eluting stents (DES) were
approved based on reduced rates of restenosis compared with
bare-metal stents (BMS) (3–5), patients with CTO were excluded
from these trials. To date, 1 small prospective randomized trial
(n 200) has examined the use of DES compared with BMS in
TO (6). Given the risks of revascularization in the elderly
represented in practice as patients of Medicare age or older) and
he greater complexity of CTO, the comparative safety and
eal-world outcomes of DES and BMS in patients undergoing
ercutaneous recanalization of total occlusions are needed to
nform clinical practice.
We used data from the NCDR (National Cardiovascular
ata Registry) CathPCI Registry linked to Centers for
edicare and Medicaid Services’s national inpatient claims
atabases to: 1) examine the clinical and procedural char-
cteristics of elderly patients undergoing recanalization for
TO with DES and BMS; and 2) compare the outcomes of
ES versus BMS implantation for CTO after adjusting for
ifferences in baseline demographics and clinical character-
stics. Specifically, the short- and long-term rates of death,
yocardial infarction (MI), repeat revascularization, and
leeding requiring hospitalization were evaluated.
ethods
Data source. The study cohort was obtained from the
CathPCI Registry, a national invasive catheterization reg-
istry cosponsored by the American College of Cardiology
and the Society for Coronary Angiography and Interven-
No. HHSAA290-2005-0032—TO4-WA1 as part of the Developing Evidence to
Inform Decisions about Effectiveness (DEcIDE) program. The authors of this report
are responsible for its content. Statements in the report should not be construed as
endorsement by the Agency for Healthcare Research and Quality or the U.S.
Department of Health and Human Services. Additional support was obtained from
the National Cardiovascular Data Registry, American College of Cardiology, Wash-
ington, DC. Dr. Patel has received research grants from NHLB, AHRQ, Johnson
and Johnson, AstraZeneca and Maquet and consulted for Bayer, Baxter, Pleuristem,
and OrthoMcNeil Jansen. Dr. Marso has a relationship with The Medicines
Company, Novo Nordisk, Abbott Vascular, Amylin Pharmaceuticals, Boston
Scientific, Volcano Corporation, and Terumo Medical. Dr. Anstrom has received
M
ations (7–9). Data on patient and hospital characteristics,
clinical presentation, treatments, and in-hospital outcomes
for PCI procedures from over 1,000 sites across the United
States are entered by sites into NCDR-certified software
and exported in a standard format. There is a data quality
program that includes both data quality report specifications
for data capture and transmission and an auditing program.
The prospectively defined variables are available on the
NCDR’s website (10).
Study population. This study included all Medicare-linked pa-
ients65 years of age undergoing PCI who were enrolled in the
athPCI Registry from January 1, 2005, to December 31, 2008,
sing the version 3 data collection form (11,12). To define a
ohort that closely resembles an acceptable clinical working defi-
ition of CTO, patients were excluded who had acute coronary
yndromes emergent or urgent indications for cardiac catheteriza-
ion or cardiogenic shock. In addi-
ion, subjects were excluded who
ad congenital heart disease, in-
tent PCI, prior coronary artery by-
ass graft (CABG), or cardiac
ransplant. Finally, only patients un-
ergoing PCI for native vessel
TO (defined as 100% stenosis in a
ajor epicardial coronary artery)
ere included in the analysis (On-
ine Fig. 1).
The PCI procedure codes
00.66, 36.0x, 37.22, 37.23, and
8.5x, except 88.59) from the Inter-
ational classification of Diseases-
inth Revision-Clinical Modifica-
ion (ICD-9-CM) were used to
dentify index procedures in the
edicare files that were then linked
o NCDR records using indirect
dentifiers (nonunique fields that
hen used in combination may
dentify unique hospitalizations), as previously described (12).
atients receiving1 stent type (i.e., both BMS and DES) were
xcluded from the analysis. The Duke University Medical Center
nstitutional Review Board granted a waiver of informed consent
nd authorization for this study.
esearch support from AstraZeneca, Eli Lilly and Company, Medtronic, and
roctor and Gamble; has served as a consultant for Abbot Vascular, AstraZeneca,
ristol-Myers Squibb, and Ikaria; and has served on Data Monitoring Commit-
ees for Pfizer and Vertex. Dr. Shunk had received institutional research support
rom, Abbott Vascular, Siemens Medical Systems, InfraredX and Gilead. Dr.
urtis holds stock in Medtronic and receives salary support from the Analytical
enter for American College of Cardiology National Cardiovascular Data
egistry. All other authors have reported that they have no relationships relevant
o the contents of this paper to disclose.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CI  confidence interval
CTO  chronic total
coronary occlusion(s)
DES  drug-eluting stent(s)





IPW  inverse probability
weighted
MI  myocardial infarction
PCI  percutaneous
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1056Clinical endpoints. For this study, 4 primary clinical end-
oints were evaluated: death, MI, repeat revascularization
rocedures (including both PCI and CABG after the index
ospital stay), and bleeding requiring hospitalization (13).
eath was defined both during the index PCI procedure
using CathPCI Registry information) and after discharge
using the Medicare denominator file). Other clinical end-
oints were defined after discharge with the Medicare
laims file using the primary diagnosis for the hospital
dmission. The ICD-9-CM diagnosis codes used to iden-
ify events were MI (410.X1), major bleeding (430 to 432
intracerebral], 578.X [gastrointestinal tract], 719.1X [hemar-
hrosis], 423.0 [hemopericardium], 599.7 [hematuria], 626.2,
26.6, 626.8, 627.0, 627.1 [vaginal], 786.3 [hemoptysis], 784.7
epistaxis], or 459.0 [hemorrhage not otherwise specified]),
nd revascularization (ICD-9-CM procedure codes for PCI:
6.00, 36.06, 36.07, 36.09, and CABG: 36.10-19).
Statistical analysis. Baseline characteristics for the CTO
population and propensity score-matched cohorts were
categorized by stent type (DES vs. BMS) and summarized
as counts and percentages for categorical variables and
mean  SD for continuous variables. Differences between
roups were compared using chi-square tests for categorical
ariables and the Wilcoxon rank sum or Kruskal-Wallis test
or continuous variables. To examine the amount of bias
eduction from the propensity score matching, standardized
ifferences from the overall cohort and the propensity score
ohort were plotted for all variables in the propensity score
odel. Statistical significance was defined as p  0.05, with
o correction for multiple comparisons. SAS statistical
oftware (version 9.2, SAS Institute, Cary, North Carolina)
as used for all calculations.
Unadjusted estimates of the event rates for clinical end-
oints at 1, 12, and 30 months following intervention were
ased on weights that were functions of Kaplan-Meier
ensoring estimates (14). The cumulative incidence rates for
ime-to-event clinical outcomes were estimated by using the
ray method (15). Unadjusted estimates of hazard ratios
HR) comparing DES with BMS were calculated using a
ox model with type of stent as the only covariates.
For adjusted analyses, the propensity score model was
reated among CTO patients for comparing DES with
MS (16). Propensity scores represent the estimated prob-
bilities of patients receiving 1 device type versus another, in
his case conditioned on 77 observed covariates (Online
ppendix). The propensity score logistic regression models
ad C indexes of 0.727. The Greedy 5¡ 1 Digit Matching
lgorithm was employed to match each pair of device types
ased on the propensity scores (17). After matching, the
istribution of estimated propensity scores for patients with
ES closely matched those for patients with BMS, as
videnced by the 5-number summaries (minimum; 25th,
0th, and 75th percentiles; maximum) describing the curves
or patients receiving each type of device: DES (29.6%, t2.5%, 72.6%, 82.8%, 97.7%); BMS (27.8%, 62.5%, 72.6%,
2.8%, 97.7%). Adjusted HR comparing each pair of device
ypes for the propensity score-matched cohort were calcu-
ated using a Cox proportional hazards model with an
ndicator variable for DES. An inverse probability weighted
IPW) method was also used as secondary approach to
alculate adjusted HR (18).
esults
Study population. From January 1, 2005, to December 31,
008, 158,422 patients 65 years of age underwent elective
CI with stent implantation and 92,069 (58.2%) were
inked to Medicare longitudinal records. Of these 92,069
atients, 10,766 (11.7%) met the specified clinical working
efinition of a CTO. After excluding 505 patients who had
oth DES and BMS used for PCI, 10,261 patients under-
oing elective PCI for CTO formed the analysis cohort.
he PCI success rates were 97.05% in the Centers for
edicare and Medicaid Services–matched population and
7.36 in the population that did not match to the Centers
or Medicare and Medicaid Services. Compared with the
opulation eligible for Medicare linkage who were unlinked,
hose linked to Medicare records were slightly older, more
ften women, and less often insured.
Baseline patient characteristics by stent type. Of the
edicare-linked cohort of stable patients with CTO un-
ergoing elective PCI (n  10,261), DES was used for
TO PCI in 8,218 (80%) patients, and BMS was used in
,043 (20%). Propensity matching was done in 4,034
atients (2,017 treated with DES and 2,017 treated with
MS). Unadjusted baseline characteristics by type of stent
eceived are shown in Table 1. Compared with BMS
ecipients, patients who received a DES for CTO PCI were
lightly younger (74.0 vs. 75.5 years, p  0.001) and less
ikely to have heart failure (57.7% vs. 60.1%, p  0.048),
eripheral vascular disease (16.3% vs. 19.9%, p  0.001), or
enal failure requiring dialysis (1.4% vs. 3.1%, p  0.001).
Procedural characteristics and outcomes. Procedural char-
cteristics were different between patients undergoing total
cclusion PCI with DES than with BMS (Table 1).
atients treated with DES for CTO PCI were likely to have
onger lesions (18.8 vs. 16.5 mm, p  0.001), more stents
2 stents in 45.7% vs. 37.9%, p  0.001), and undergo
ultivessel PCI (18.9% vs. 15.1%, p  0.001), when
ompared with BMS.
Unadjusted procedural outcomes during total occlusion
CI by stent type are presented in Table 2. When compar-
ng patients who received DES versus BMS for CTO PCI,
ajor periprocedural complications were similar, including
ascular access complications (0.8% vs. 1.2%, p  0.072), as
ell as general complications (2.6% vs. 3.2%, p  0.13),
ncluding renal failure (0.2% vs. 0.2%, p  0.86) and
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1057Comparison of DES versus BMS outcomes. MORTALITY AND
YOCARDIAL INFARCTION. Medicare patients undergoing
CTO PCI treated with DES rather than BMS had lower
unadjusted rates of death (12.3% vs. 21.1%, p  0.001)
Fig. 1A). Examination of the adjusted analyses, including
he propensity score-matched cohort (adjusted HR: 0.72,
5% confidence interval [CI]: 0.60 to 0.86, p  0.001)
nd the IPW HR (HR: 0.67, 95% CI: 0.59 to 0.77, p 
.001) demonstrates findings similar to the unadjusted
ata (Fig. 2).
The unadjusted incidence of MI at 30 months in patients
reated with DES was similar for patients treated with BMS
5.1% vs. 6.3%, p  0.36) (Fig. 1B). This finding was






(n  2,043) p Value
Age, yrs 74.3 6.5 74.0 6.4 75.5 6.9 0.001
Male 6,996 (68.2) 5,637 (68.6) 1,359 (66.5) 0.072
Caucasian 8,967 (87.5) 7,194 (87.7) 1,773 (86.9) 0.329
Current smoking 1,246 (12.1) 976 (11.9) 270 (13.2) 0.096
CHF 5,966 (58.2) 4,739 (57.7) 1,227 (60.1) 0.048
HTN 8,501 (82.9) 6,787 (82.6) 1,714 (83.9) 0.15
No dialysis renal failure 489 (4.8) 370 (4.5) 119 (5.8) 0.012
Dialysis renal failure 180 (1.8) 117 (1.4) 63 (3.1) 0.001
PVD 1,747 (17.0) 1,341 (16.3) 406 (19.9) 0.001
Diabetes
Noninsulin 2,633 (25.7) 2,127 (25.9) 506 (24.8) 0.306
Insulin 926 (9.0) 738 (9.0) 188 (9.2) 0.751
Stroke 1,543 (15.0) 1,181 (14.4) 362 (17.7) 0.001
Chronic lung disease 1,762 (17.2) 1,353 (16.5) 409 (20.0) 0.001
Prior PCI 3,492 (34.0) 2,918 (35.5) 574 (28.1) 0.001
Prior MI 3,409 (33.2) 3,409 (33.2) 2,710 (33.0) 0.289
Positive noninvasive test 7,254 (86.7) 5,878 (87.4) 1,376 (83.5) 0.001
Procedural characteristics
Multivessel PCI 1,859 (18.1) 1,550 (18.9) 309 (15.1) 0.001
Number of vessels
intervened
1 8,402 (81.9) 6,668 (81.1) 1,734 (84.9) 0.001
2 1,758 (17.1) 1,466 (17.8) 292 (14.3) 0.001
3 101 (1.0) 84 (1.0) 17 (0.8) 0.436
Intervened vessel
LAD 4,757 (46.4) 3,934 (47.9) 823 (40.3) 0.001
LCX 3,720 (36.3) 2,957 (36.0) 763 (37.3) 0.251
RCA 3,074 (30.0) 2,421 (29.5) 653 (32.0) 0.027
Stents per patient
1 5,729 (55.8) 4,460 (54.3) 1,269 (62.1) 0.001
2 4,532 (44.2) 3,758 (45.7) 774 (37.9) 0.001
Lesion length, mm 18.4 10.7 18.8 10.9 16.5 9.5 0.001
Values are mean SD or n (%).
BMSbare-metal stent(s); CHF congestive heart failure; DESdrug-eluting stent(s); HTN
hypertension; LAD left anterior descending; LCX left circumflex; MImyocardial infarction;
PCI  percutaneous coronary intervention; PVD  peripheral vascular disease; RCA  right
coronary artery.onfirmed with the propensity score-matched adjusted cohortR (HR: 0.85, 95% CI: 0.61 to 1.19, p 0.348) and the IPW
R for MI (HR: 0.81, 95% CI: 0.63 to 1.03, p  0.087) for
atients treated with DES compared with BMS (Table 3).
REPEAT REVASCULARIZATION. The unadjusted rates of
subsequent revascularization for patients treated with DES
versus BMS for CTO PCI was similar at short-term
follow-up (1 month rate: 4.1% vs. 3.3%, p  0.103) and
long-term follow-up (30 month rate: 21.7% vs. 20.4%, p 
0.62) (Fig. 1C). Examination of adjusted HR demonstrates
similar findings for both short-term and long-term revas-
cularization (Fig. 2).
Subsequent PCI in patients receiving DES versus BMS
was higher at 1 month (unadjusted rate: 4.0% vs. 3.0%, p 
0.042), and similar at long-term follow up (30 month
unadjusted rate: 18.7% vs. 16.9%, p 0.44). Examining the
propensity score-matched cohort for long-term adjusted
comparisons of subsequent PCI procedures, DES implan-
tation was associated with a similar hazard compared with
patients receiving BMS (HR: 0.98, 95% CI: 0.81 to 1.19,
p  0.87). Adjustment with the IPW method found that
differences in additional PCI rates between DES and BMS
were similar to those observed in the propensity score-
matched cohort (Fig. 2).
Unadjusted rates for subsequent CABG at long-term
follow-up in patients receiving DES versus BMS was
similar (3.0% vs. 3.5%, p 0.66). Propensity score-matched
cohort analysis for long-term CABG trended toward lower
hazard in patients treated with DES versus BMS (HR:
0.71, 95% CI: 0.46 to 1.10, p  0.12). After adjusting for
baseline differences, the IPW method demonstrated a lower












Zotarolimus eluting 288 (3.5)
Vascular complications 87 (0.8) 63 (0.8) 24 (1.2) 0.072
Access site occlusion 4 (0.01) 4 (0.01) 0 (0.0) 0.318
Peripheral embolization 3 (0.01) 2 (0.01) 1 (0.01)
Dissection 24 (0.2) 18 (0.2) 6 (0.3) 0.533
Pseudoaneurysm 53 (0.5) 37 (0.5) 16 (0.8) 0.061
AV ﬁstula 7 (0.1) 5 (0.1) 2 (0.1) 0.566
Retroperitoneal bleed 22 (0.2) 21 (0.3) 1 (0.0) 0.071
General complications 277 (2.7) 212 (2.6) 65 (3.2) 0.134
Periprocedural MI 130 (1.3) 102 (1.2) 28 (1.4) 0.642
Stroke 15 (0.1) 11 (0.1) 4 (0.2) 0.513
Tamponade 13 (0.1) 13 (0.2) 0 (0.0) 0.072
Renal failure 19 (0.2) 15 (0.2) 4 (0.2) 0.856
Values are n (%).AV arteriovenous; other abbreviations as in Table 1.
coronary occlusion (CTO) percutaneous coronary intervention (PCI).
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1058hazard for subsequent CABG (HR: 0.70, 95% CI: 0.52 to
0.94, p  0.017).
BLEEDING. DES implantation, compared with BMS im-
plantation, was not associated with a significantly lower
incidence of hospitalization for bleeding (unadjusted 30 month
rate: 3.1% vs. 4.9%, p  0.142). Between the propensity
score-matched cohort and the IPW-adjusted analysis, there
were no significant differences in 30-month bleeding rates
between DES and BMS for CTO PCI (Fig. 2).
Discussion
This national observational real-world cohort provides in-
formation on greater than 10,000 elderly patients undergo-
Figure 2. Adjusted Clinical Events for DES Versus BMS
This ﬁgure is a Forrest plot of the clinical events for DES and BMS with the
effects shown as point estimates after adjustment with propensity meth-
ods. CABG  coronary artery bypass graft; IPW  inverse probability
weighted; PM  propensity matched; REG  regular; revasc  revascular-Figure 1. Unadjusted Rates by Stent Type in Patients Undergoing
CTO PCI
Unadjusted rates of (A) death and myocardial infarction (MI); (B) revascular-
ization; and (C) bleeding requiring hospitalization for patients getting drug-
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1059ing successful elective recanalization of CTO. DES were
used in 80% of patients. These patients were typically
younger and less likely to have peripheral vascular disease,
but they were more likely to have longer stents and
multivessel revascularization. Compared with BMS implan-
tation, use of DES for revascularization of CTO was
associated with a lower long-term mortality rate. Addition-
ally, DES and BMS use at long-term follow-up had similar
rates of MI, overall repeat revascularization (PCI and
CABG), with a trend toward more subsequent PCI and less
CABG with DES. Hospitalizations for bleeding were
similar in the 2 groups. After risk adjustment, DES use for
CTO revascularization was associated with a reduced inci-
dence of death at long-term-follow up, but had similar rates
of MI, subsequent revascularization, and hospitalization for
bleeding.
These findings add substantially to the available data on
patients undergoing total occlusion recanalization with
DES compared with BMS. Although some of the patients
may have had a subacute occlusion, most of these stable
elective outpatients undergoing CTO PCI do not represent
Table 3. Unadjusted and Propensity Score-Matched Event Rates by Stent T
Outcomes*
DES
1 Month 12 Months 30 Mo
Death
Unadjusted 1.0 5.2 12
PS matched 1.1 7.1 15
IPW adjusted 1.0 5.5 13
MI, rate per 100 patients
Unadjusted 0.6 2.5 5
PS matched 0.7 3.2 5
IPW adjusted 0.5 2.1 4
Revascularization, rate
per 100 pt
Unadjusted 4.1 12.9 21
PS matched 3.9 12.1 19
IPW adjusted 4.0 11.6 17
Subsequent PCI rate
Unadjusted 4.0 11.6 18
PS matched 3.7 10.9 16
IPW adjusted 3.9 10.3 15
Subsequent CABG
Unadjusted 0.1 1.3 3
PS matched 0.3 1.2 2
IPW adjusted 0.2 1.4 2
Bleeding, rate per 100 pt
Unadjusted 0.3 1.8 3
PS matched 0.2 1.8 4
IPW adjusted 0.3 1.6 2
Values are %. *Covariates used are listed in the Online Appendix. †The p value compares DES and
IPW inverse probability weighting; PS propensity score; other abbreviations as in Tables 1 apatients randomized in the OAT (Occluded Artery Trial), twho were enrolled with an occlusion identified between 3
and 30 days after MI (19). Regarding elective CTO revas-
cularization, a small prospective randomized trial in 200
CTO patients (20) and analysis of a subgroup in the
SCANDSTENT (Stenting Coronary Arteries in Non-
Stress/Benestent Disease) trial (21) found a reduced rate of
binary restenosis and a need for target vessel revasculariza-
tion in patients treated with sirolimus-eluting stents versus
BMS. Data from these studies was recently combined in a
systematic review that included 17 published studies of DES
use in patients with total occlusions, including 8 case series
studies without controls and 7 nonrandomized observational
comparisons (22). Although this review of nearly 1,500 pa-
tients found DES use in the case of CTO was associated with
reduced angiographic restenosis, limited data with regard to
the long-term safety and clinical outcomes do not allow
correlation with the current study’s findings.
Safety and effectiveness of DES and BMS in older patients
with total occlusions. The findings from this study suggest
hat the use of DES in elderly patients with CTO revascu-
arization is associated with a lower mortality. It is possible
or CTO PCI
BMS
p Value†1 Month 12 Months 30 Months
2.3 11 21.1 0.001
2.2 10.8 20.8 0.014
2.0 10.1 17.9 0.001
0.6 3.6 6.3 0.36
0.6 3.5 6.3 0.744
0.5 3.1 5.2 0.002
3.3 12.4 20.4 0.622
3.3 12.5 20.5 0.721
4.2 13.6 18.3 0.877
3.0 10.6 16.9 0.443
3.0 10.7 17 0.888
3.9 11.3 15.7 0.336
0.3 1.7 3.5 0.645
0.3 1.7 3.5 0.535
0.3 2.5 3.9 0.071
0.4 2.0 4.9 0.142
0.4 2.0 4.9 0.512





















BMS athat there was selection bias, with DES-treated patients
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1060representing lower risk patients than the BMS-treated
patients. However, multiple important baseline characteris-
tics that predict outcomes were well balanced in the pro-
pensity score-matched cohort and adjusted for in the anal-
ysis. Possible mechanisms of the protective effect observed
with the selection for DES versus BMS include more
prolonged dual antiplatelet therapy, a lower burden of
ischemia, and improved ventricular function. Studies eval-
uating recanalization of CTO have shown that patients with
areas of viable myocardium improve their ventricular func-
tion with CTO revascularization (23). Finally, the potential
benefits of more complete revascularization, as evidenced by
the use of more stents and higher rates of multivessel PCI at
the index procedure in the DES-treated patients may
contribute to these proposed protective mechanisms.
Of note, the findings from this large observational study
of elderly patients are qualitatively consistent with findings
from the individual trials and meta-analysis of studies
comparing DES with BMS (13,24). These other studies
estimated a trend toward a reduction in both mortality and
subsequent MI. The elderly patients in this analysis with
higher baseline risk, higher coronary disease burden, and
long-term follow-up may allow detection of smaller degrees
of incremental benefit with DES over BMS, compared with
the randomized trials aimed at evaluating restenosis. Con-
servatively, these data support that DES use for CTO PCI
is at least as safe and effective as BMS use.
Repeat revascularization procedures. In this large observa-
tional study, subsequent revascularization procedures oc-
curred at similar rates in patients treated with both DES
and BMS for total coronary occlusions. These data may in
part be reconciled with prior data on repeat revascularization
with DES when the types of subsequent revascularization are
reviewed. Evaluation of the subsequent revascularization
mode shows that, although not statistically significant,
patients receiving DES, compared to BMS-treated patients,
had higher absolute rates of subsequent PCI and lower
absolute rates of CABG. In fact, these small absolute
differences were present starting at 30 days and continued at
30 months. After adjusting for baseline characteristics and
applying propensity score matching, these trends hold with
regard to risk of subsequent revascularization.
These findings likely underscore a treatment strategy for
patients with CTO where DES implantation was associated
with a higher likelihood of multivessel PCI at index proce-
dure and subsequent PCI within 30 days, compared with
BMS-treated patients where the decision to attempt com-
plete percutaneous revascularization may not have been
made. In fact, within this dataset, the subsequent site of
revascularization (such as target lesion revascularization)
cannot be identified and may represent staged revascular-
ization of other coronary stenosis. The lack of a significant
difference in subsequent revascularization in this observa-
tional study may be in part also explained by the significantdifference in observed mortality, the potential for planned
subsequent revascularization in DES patients getting CTO
PCI, and the potential for incomplete adjustment for
operator selection of lower restenosis risk patients for BMS
and higher restenosis risk patients for DES. Nevertheless,
the findings of similar revascularization rates with both
DES and BMS are discordant from randomized trials and
may represent bias around case selection. Despite these
potential biases, combined with the observed mortality and
MI outcomes, the revascularization findings for DES use
are reassuring.
Although a longer duration of dual antiplatelet therapy is
typically prescribed with DES, we observed lower unad-
justed bleeding rates with selection for DES rather than
BMS in this study. This may reflect unaccounted-for factors
in matching stent type to estimated patient bleeding risk by
physicians. Supporting this idea, the propensity score-
matched and IPW rates for bleeding were not significantly
different for DES versus BMS.
Strengths and limitations. As with all observational studies,
there are several important points to consider when inter-
preting the results of this study. First, we must consider the
data source. The CathPCI Registry represents over 1,000
U.S. hospitals and, therefore, a significant portion of PCI
nationally. Patients over 65 years of age compose more than
50% of patients undergoing PCI. This is a real-world cohort
of consecutive older patients with CTO undergoing elective
revascularization; as such, many of these patients would
have been excluded from the pivotal trials, due to the lesion
complexity and/or associated comorbidities. As with all
studies from the NCDR, there is the potential for case
selection bias, as well as operator and institutional variation.
The second important consideration is the duration of
follow-up and data collected. Because the follow-up informa-
tion was linked to the Medicare administrative data files, we
were able to obtain long-term incidence of death, MI, revas-
cularization, and bleeding associated with hospitalization. Yet
because the registry data are linked with administrative data, it
is not possible to determine target vessel revascularization or
stent thrombosis through ICD-9 coding. However, all addi-
tional revascularization procedures (PCI or CABG), MI, and
death are captured—arguably, these additional procedures are a
more important patient-centered outcome.
Although important determinants of both angiographic and
clinical outcomes were collected (i.e., baseline comorbidities
and procedural characteristics, such as the number of stents,
stent length, and vessels intervened per patient), data on other
important factors (i.e., medication during follow-up and ana-
tomic factors, such as vessel caliber and lesion length) were not
captured. Additionally, duration of CTO was not known,
although this is considered a stronger determinant on elective
PCI success, and as mentioned previously, all patients with
recent acute coronary syndrome emergent indications were
excluded. The inability to capture all potential determinants of
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1061outcomes could bias the observation toward no significant
difference between DES and BMS.
Finally, as in all observational studies, there remains the
possibility of unmeasured confounders that could influence
the use of a DES instead of a BMS for patients with CTO.
This study used a large number of variables in the multi-
variable adjustment and replicated the results using 2
different statistical approaches.
Conclusions
In a large national consecutive cohort study of Medicare
beneficiaries undergoing elective PCI for CTO, 80% of pa-
tients received DES. In a propensity score-matched cohort,
these older patients who received DES had significantly lower
mortality rates throughout 30 months of follow-up than did
those who received BMS. There was no significant difference
in long-term rates of MI, repeat revascularization, or bleeding
requiring hospitalization. These data add significantly to avail-
able data on DES in elective CTO revascularization, providing
evidence of safety and efficacy in routine practice in this large,
high-risk group of elderly patients.
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APPENDIX
For additional data and a supplemental figure, please see the online version
of this paper.
